David Lebwohl - Aug 9, 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Medical Officer
Signature
/s/Glenn Goddard, Attorney-in-fact
Stock symbol
NTLA
Transactions as of
Aug 9, 2021
Transactions value $
-$363,432
Form type
4
Date filed
8/11/2021, 04:50 PM
Next filing
Sep 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise $30.3K +2.4K +303.41% $12.62 3.19K Aug 9, 2021 Direct
transaction NTLA Common Stock Sale -$394K -2.4K -75.21% $164.05 791 Aug 9, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Options Exercise $0 -2.4K -1.2% $0.00 198K Aug 9, 2021 Common Stock 2.4K $12.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 Includes 568 and 223 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020 and June 30, 2021, respectively.
F3 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 62,500 shares as of August 9, 2021.